POTELIGEO® (mogamulizumab-kpkc) is a humanized monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain hematologic malignancies including cutaneous T-cell lymphomas (CTCL), such as mycosis fungoides (MF) and Sézary syndrome (SS). By binding to CCR4 on malignant T-Cells, POTELIGEO® elicits an antitumor activity mediated by antibody-dependent cellular cytotoxicity (ADCC) leading to the death of malignant T-Cell.
POTELIGEO® was produced using Kyowa Kirin's proprietary POTELLIGENT® platform.